Sign in Subscribe
Atopic dermatitis

OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, and Market Opportunity Insight

Strategic Insights

— 1 min read

The market for OX40/OX40L targeted therapies is rapidly evolving, with pharmaceutical investment and academia interest converging to bring forth a vibrant pipeline of contenders. Several candidates are currently in late-stage trials, and innovation is extending into combination strategies as well as diagnostic pairing. This report provides an overview of the fast-evolving space, highlighting the drivers making it happen.

Key Takeaways:

  • The first OX40 targeted therapy approval is expected by 2030.
  • 10 OX40 targeted therapies are currently in clinical trials.
  • Cancer dominates the OX40 targeted therapies clinical trials landscape.
  • The report provides OX40 targeted therapies clinical trials insight by company, country, indication, and phase.
  • The competitive landscape of OX40/OX40L targeted therapies is diverse, with multiple companies active in R&D.
  • The autoRx40 Platform is a proprietary therapeutic development engine that targets OX40 and other related immune receptors.
  • Several leading companies are making bets in the OX40/OX40L therapy arena, including Sanofi, Amgen, Astria Therapeutics, and ImageneBio.
  • OX40/OX40L therapies are progressing beyond monotherapy to combinations based on disease severity and patient profile.
  • Future contenders are being developed for longer half-life, less immunogenicity, and better patient compliance.
  • OX40/OX40L therapies have the potential to set new standards in immune disease therapy.

Statistics:

  • 10 OX40 targeted therapies are currently in clinical trials.
  • The first OX40 targeted therapy approval is expected by 2030.
  • Cancer dominates the OX40 targeted therapies clinical trials landscape.
  • The autoRx40 Platform is a proprietary therapeutic development engine that targets OX40 and other related immune receptors.
  • Multiple companies active in R&D, including Sanofi, Amgen, Astria Therapeutics, and ImageneBio.
  • 7,000+ people participated in OX40/OX40L targeted therapy clinical trials between 2020 and 2023.
  • The market size of OX40/OX40L targeted therapy is expected to reach $1.2 billion by 2026.

Sources:

  • "OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026"
  • ResearchAndMarkets.com
  • businesswire.com
  • https://www.researchandmarkets.com/r/tr3oj2

Read more